{"name":"Alaunos Therapeutics","slug":"alaunos-therapeutics","ticker":"","exchange":"","domain":"","description":"Alaunos Therapeutics is a biopharmaceutical company focused on the development of innovative oncology treatments. The company has a diverse pipeline of 17 drug candidates, with several in early-stage clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":15900000,"revenueGrowth":0,"grossMargin":0,"rdSpend":362000,"netIncome":-4679000,"cash":2755000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Darinaparson","genericName":"Darinaparson","slug":"darinaparson","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Darinaparson","genericName":"Darinaparson","slug":"darinaparson","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOVFkxcWNCNTZGQ2pWVWhuNWgwVEsyU19qZmMyRWFTcUQwS1hFOEJBb3ZxeS1uNXdzdmFQaEZVdlZGS00wOFVPeFJhYnZmbU14OHJvYU9JZTVtSGNXSG91M2ItcnQwMlhUNUUyRmFqaHlnekVKVGJjZmlrTWszV09zWEpFbXBFMGxwY1VER0ZXS2tiSmNnMnJqb04zTDBJdzNBSG93RDU2SQ?oc=5","date":"2026-02-09","type":"deal","source":"Pharmaceutical Technology","summary":"Eli Lilly bets on in vivo cell therapy in $2.4bn Orna Therapeutics buyout - Pharmaceutical Technology","headline":"Eli Lilly bets on in vivo cell therapy in $2.4bn Orna Therapeutics buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQUFlhdWhJcVUwTW43NUFLdERoMnhXOTdzNmJqVkgyTXpHWXF5WU5ZZFdxMGZDSjltUVBvWU80UElPeXA0X3NMU05ieHRaUmRJQ3JzU1NwQnVKbERGU3J4OXRwemw4RlFIWHI2QXNBbFctM3FnMDlMWWFxWFIxcU9kQ1pwVkI4OERzWGhEbnhUNjZIUQ?oc=5","date":"2026-01-21","type":"deal","source":"Pharmaceutical Technology","summary":"Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies - Pharmaceutical Technology","headline":"Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNeGQ5RnJ0dG5KY05mZ1NUb25fMmNTc1E3X3ljOTN0U0xJVXJsbktjQzE0TGlXSjE0cFJ6Z1BNX2pCTXpzR0pQbThZcU9FNVBIRHhUYUNkUUtUTW5qbVRrWU81TkNGQVZJcENWWS1nOWhONlV0TUhsdmZMX0dlYThNNE5CMUF3UENzVHJORGE4MmxpMmFNU09wdFEtclBGUQ?oc=5","date":"2026-01-09","type":"pipeline","source":"Pharmaceutical Technology","summary":"Alveus debuts in obesity arena with $160m Series A - Pharmaceutical Technology","headline":"Alveus debuts in obesity arena with $160m Series A","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQOEkxb2liOWJEZG40THRuclJBVm1RbWxDRzRSZFBiVndSOEF2aG5kLTdlQUp4ZVBadHBQMFVDeFc2ZUw5NkNETW5KZnBmVmJ5aVBGelI5eDNyeDVhMmp4ZXlLU0thQVNNU3VZdHVoX1lWX01vTzJwSWxXS25EY0xZZ0NPWFN3Z3VDeGYwMkNfNGhWR3I3djJjTnFfUFU3a2d2VlhSaU9UMFcwY2xvRTlvM1NZNUROR1U?oc=5","date":"2025-12-10","type":"pipeline","source":"Pharmaceutical Technology","summary":"Cell and gene therapy investment strategy pivots as funding dries up - Pharmaceutical Technology","headline":"Cell and gene therapy investment strategy pivots as funding dries up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOYW9UYU1aSzNuMWZFVXl4MGNzajBiUVdGeUtxa3pWWDZvYUs5X0U4ZXdlR1dnNGJqV0FzYUUxRklKSkZ6Q3VhZ2MtcDBUeFk5N21YbzJIemlWVF9FWlpJYm9JeWU1b0VLNktuek5wbG1qVWRUcU5sWFN3a3d2TGlEZGNvZkFmdG1vdmhpdWxoWGNYRWFxa1JWS1Iwd1JvVFh0M0w4a1Y4M1BTY3Qtb3ozUUNURERsclU?oc=5","date":"2025-11-25","type":"pipeline","source":"Pharmaceutical Technology","summary":"Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m - Pharmaceutical Technology","headline":"Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOcTFvLWRvbUFMMWNJOW96aFZ1UWJQVW1jVzlVa2hZZ1RkdkhUTHZRT2pjZzROMGxPZklMc3VwVktTQ2VCa3g2Vld1OUlkRVY0OVo1bFRDRmhIY0hyakxvdVFjelBaSnJiRzIyaEpLZzJQN3piUm5RV1IzblduMkdBODdVNkZyR1B5cWVBcmNVbWllNHc4VTlwNTN3OVFWYUh3V1JsREd0eHlrZGlOTkE0?oc=5","date":"2025-08-22","type":"pipeline","source":"Pharmaceutical Technology","summary":"Gilead’s Kite scoops in vivo CAR-T specialist Interius for $350m - Pharmaceutical Technology","headline":"Gilead’s Kite scoops in vivo CAR-T specialist Interius for $350m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNbGdpdUFEc0xHX0xmZEhjY09WU1czdzFsdnZLOFJraE4tTHRhZjJPbFNzemphVTAzNjJNbm9CV0RCbXQ3dzNJOWV0bzBONThVLU5qVUItdTJGOWJQQjIydHhNT1NtX3g1S2pCZkRKOFdXNDNBQWxlM3I3OGJZUThWRzZfYnphamtXQnRrZE04Nkt0Vmp3blFKTFh3?oc=5","date":"2025-06-06","type":"pipeline","source":"Pharmaceutical Technology","summary":"Juvenescence enhances AI drug discovery with Ro5 acquisition - Pharmaceutical Technology","headline":"Juvenescence enhances AI drug discovery with Ro5 acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBhb2RTZGNBMWxkWmlIaUpfWXFrZ3pXbDFJS3hkcE9ZTmxXTGRFRGhnLUQ1RlF2N1VwcmVrVWFadXRrR2ZHR2J3T3BvNThCQ2NzRFJr?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"TCRT Stock Price, News & Analysis - Stock Titan","headline":"TCRT Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNcTBLTW40cENlazdoUnVBcWFZeHZna3RZRnE3WmpkZ2pHUWhvcV9kc05YNkNUa0ZWMUZyUjFFU0pRQUVTUHNhRTJuVDZwRWhPaHZ0VWZ3SFBaRGMxYnpyelV4TFk3V19hS1dzNi1IQ0o0OXNZOUUzd2VIY2VVS3RudWtoc0wxcFdsS3o1VHhKZFppY3hrRGVJNllfYTBGckJJTndKLXJZSW1XV2lxNV9aRm1OczRDRlZB?oc=5","date":"2025-01-10","type":"deal","source":"Pharmaceutical Technology","summary":"Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology","headline":"Light Horse emerges with $62m and Novartis partnership worth up to $1bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNOVEySDZxRFR3dHUyRFVGMzl0bkt2aEVDLXJYLXdINUc5SVJ1eElUaDZ6Q3hJMGpXbHFQWFduM25aY1o1ZGFXQTdqdHZiUjJpbU0zZzlfVE1yX0M4UTRHUkZxWUFsNnhraFdRLXJwejVaVkozbkNnaVZHSWczXzZzWFNLNExBUFVJT25CYjJGN0hqVGcxbVdqdjZkWHhpUVVTUnFkQUNBdFBwNl9QdkFPeENDaw?oc=5","date":"2024-10-11","type":"pipeline","source":"Fierce Biotech","summary":"After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech","headline":"After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":15900000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":15900000,"period":"2017-12-31"},{"value":15900000,"period":"2017-12-31"},{"value":200000,"period":"2013-12-31"},{"value":200000,"period":"2013-09-30"},{"value":200000,"period":"2013-06-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":362000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-4679000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":2755000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}